Quick Takeaways
- James Healy has 9 issuer positions tracked on this page.
- Estimated disclosed ownership value: $293,364,111.
- Recent insider filing activity is available below.
- Info
- Insider Ownership
Insider Trading & Ownership of James Healy
- Location
- Menlo Park, CA
- Summary
- The estimated net worth of James Healy is at least $293,364,111 dollars as of 18 Sep 2025. James Healy is the Director of Natera, Inc. and owns shares of Natera, Inc. (NTRA) stock worth about $225.77M. James Healy is the Director of BioAge Labs, Inc. and owns shares of BioAge Labs, Inc. (BIOA) stock worth about $41.49M. James Healy is the Director of Rapport Therapeutics, Inc. and owns shares of Rapport Therapeutics, Inc. (RAPP) stock worth about $19.92M. James Healy is the Director of ArriVent Biopharma, Inc. and owns shares of ArriVent BioPharma, Inc. (AVBP) stock worth about $6.19M.
- Signature
- /s/ John LaRocca, Attorney-in-Fact
- All Insider Reports
- All Insider Reports
Follow Filing Activity
Follow James Healy and return when a new Insider Trading filing changes the record on this page.
This uses the existing product follow flow to surface future filing-backed changes without guessing what they mean.
What Changed
- Largest disclosed position: Natera, Inc. ($225,766,720).
- Past-year value change for that position: .
Why This Matters
- This page translates Forms 3/4/5 into a quick ownership context before you inspect each transaction row.
- You can cross-check role, issuer, and filing chronology directly against the SEC source.
Source Evidence
Filed on Form 4
See Original Filing
Insider ownership context is sourced from SEC Forms 3, 4, and 5.
Ownership of James Healy
| Symbol | Company | Relationship | Holdings Value | Past Year Net Change | Change % | Report Period |
|---|---|---|---|---|---|---|
| NTRA | Natera, Inc. | Director | $225,766,720 | 25 Apr 2025 | ||
| BIOA | BioAge Labs, Inc. | Director | $41,488,218 | 05 Jun 2025 | ||
| RAPP | Rapport Therapeutics, Inc. | Director | $19,916,028 | 17 Jun 2025 | ||
| AVBP | ArriVent Biopharma, Inc. | Director | $6,193,145 | 30 Jan 2024 | ||
| KRTX | Karuna Therapeutics, Inc. | Director | $0 | 18 Mar 2024 | ||
| YMAB | Y-mAbs Therapeutics, Inc. | Director | $0 | 16 Sep 2025 | ||
| BOLT | Bolt Biotherapeutics, Inc. | Director | 12 Jun 2024 | |||
| CINC | CinCor Pharma, Inc. | Director, 10%+ Owner | 28 Nov 2022 | |||
| CHRS | Coherus BioSciences, Inc. | Director | 07 Jan 2022 |
Insider Transactions Reported by James Healy:
| Sym | Company | Class | Transaction | % | Value $ | * Price $ | Shares | Shares After | Date | Ownership |
|---|
* An asterisk sign (*) next to the price indicates that the price is likely invalid.